Pharmaceutical News

RSS

Potential harms associated with some drugs used for treating COVID-19 patients

Chloroquine, hydroxychloroquine and azithromycin are being used to treat and prevent COVID-19 despite weak evidence for effectiveness, and physicians and patients should be aware of the drugs' potentially serious adverse events, states a review in CMAJ.

8 Apr 2020

What are the environmental effects of chemotherapeutic drugs?

Chemotherapeutic drugs, also known as antineoplastic agents, that are prescribed to treat a range of cancer types, enter the aquatic environment via human excretion and wastewater treatment facilities.

8 Apr 2020

Promise in reversing kidney damage caused by lupus shown by cancer drug

A drug used for cancer therapy has shown promise in reversing kidney damage caused by systemic lupus erythematosus.

8 Apr 2020

Bill and Melinda Gates fund potential vaccine against COVID-19

In a race against time, teams of scientists across the world are working towards developing an effective and safe vaccine to prevent infection from the SARS-CoV-2 virus that causes COVID-19 disease.

7 Apr 2020

USC scientists report wider benefits of well-known hangover drug

A well-known hangover drug not only helps soothe pounding headaches but also triggers profound changes that protect the liver, USC scientists report in new findings that could help prevent alcohol-related harm.

7 Apr 2020

USC researchers show wider benefits to drug used for hangovers

A well-known hangover drug not only helps soothe pounding headaches but also triggers profound changes that protect the liver.

7 Apr 2020

COVID-19 and renin-angiotensin system inhibitors

A new viewpoint article published in the journal JAMA Network in April 2020 deals with the use of a widely used category of cardiovascular medications in COVID-19 patients with hypertension, diabetes, and cardiovascular disease (CVD). These are the most common medical conditions that are found in COVID-19 patients and contribute disproportionately to mortality.

5 Apr 2020

Who should be taking antimalarial drugs as treatment against COVID-19?

Researchers provide a guideline regarding who should be actually taking antimalarial drugs as prophylaxis to prevent getting COVID-19. They say health professionals who are being exposed to COVID-19 positive patients and those who test positive but are asymptomatic should be taking drugs such as Chloroquine and Hydroxychloroquine. They explain that these populations remain most in need, and because of limited supply, these individuals need to be prioritized.

2 Apr 2020

Promising vaccine patch candidate for COVID-19

In a breath of fresh air, scientists from the University of Pittsburgh School of Medicine reported that they had developed a potential new vaccine against the SARS-CoV-2 virus, which is causing the current COVID-19 pandemic. The vaccine has been tested in mice. When administered through a small patch only the size of a fingertip, the vaccine was found to generate protective neutralizing antibodies against the virus, in adequate quantities.

2 Apr 2020

Pancreatitis drug Nafamostat shows promise for coronavirus

With the increasing number of infections across the globe, scientists have resorted to studying existing drugs in the hope of discovering a cure for the coronavirus disease (COVID-19). A team of researchers has found that an existing drug, Nafamostat or Fusan, a drug used to treat acute pancreatitis, may effectively block the process used by the novel coronavirus to spread and cause illness.

1 Apr 2020

Researchers say that NSAIDs, JAK inhibitors and TNF blockers are safe to use in COVID-19

Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.

1 Apr 2020

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.

31 Mar 2020

Two newer types of diabetes medications show heart and kidney benefits

Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

31 Mar 2020

Scientists could soon develop saliva test for measuring cannabis levels in impaired drivers

In the U.S., those who consume alcohol and drive are often subjected to roadside stops, breathalyzer tests and stiff penalties if their blood alcohol content exceeds certain limits.

31 Mar 2020

Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome

Patients with acute coronary syndrome (ACS) who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for nine months had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

31 Mar 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

New study helps identify drugs that are safe for treating COVID-19

A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

31 Mar 2020

How long to a coronavirus vaccine?

The whole world is waiting for one. A vaccine is the only thing that could conceivably save the world from a horrifying cascade of deaths, other than a miracle, it seems.

29 Mar 2020

Will 'old faithful' tuberculosis BCG vaccine work against COVID?

All over the world, except in China, the place where it all began, the COVID-19 pandemic is making its relentless way through the population. So far, it has caused nearly 34,000 deaths – and the situation in the US is still worsening with over 142,000 cases and 2,489 deaths. In Australia, the number of cases has climbed to 4,093, with 16 fatalities.

29 Mar 2020

FDA approves immune-modulating therapy for treatment of multiple sclerosis

The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis.

26 Mar 2020